New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
12:47 EDTIPSEYIpsen, Galderma increase collaboration for Dysport in new territories
Ipsen and Galderma announced that their collaboration for the promotion and distribution of Dysport, Ipsenís botulinum toxin type A in aesthetic indications, has been extended. Both companies renewed their collaboration in Brazil and Argentina and extended their partnership to Australia where Galderma has the exclusive promotion and distribution rights for Ipsenís Dysport in glabellar lines indication. Both companies also entered into a co-promotion agreement in South Korea where Galderma and Ipsen will co-promote Dysport and Restylane.
News For IPSEY From The Last 14 Days
Check below for free stories on IPSEY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2014
10:41 EDTIPSEYIpsen announces acceptance of filings for Somatuline for GEP-NETs1 treatment
Ipsen N.A., an affiliate of Ipsen announced that the FDA has accepted and granted priority review of its supplemental New Drug Application, sNDA, for Somatuline Depot 120mg injection in the treatment of gastroenteropancreatic neuroendocrine tumors, GEP-NETs. The FDA designates priority review status to drug candidates that have the potential to offer a significant improvement in treatment compared to currently approved options. A decision is expected in early Q1, 2015. The regulatory submission was supported by the results of the investigational CLARINET Phase III study, which demonstrated the antitumor effect of Somatuline in the treatment of patients with GEP-NETs, and which was recently published in the July 17th issue of The New England Journal of Medicine.
08:52 EDTIPSEYIpsen says FDA accepts Somatuline Depot for priority review
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use